Survival Outcomes for Men over 80 Years Undergoing Transrectal Ultrasound-Guided Prostate Biopsy: A Prospective Analysis

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Dec 17

PMID 39682181

Authors

Dareen Alghamdi

Neil Kernohan

Chunhui Li

Ghulam Nabi

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is the second most prevalent cancer among elderly males in Western countries. TRUS biopsy remains a standard diagnosing approach for prostate cancer but poses notable risks, particularly in older men, including complications such as sepsis, acute retention, and rectal bleeding, which can lead to substantial morbidity and mortality. This study aimed to evaluate cancer-specific survival outcomes in men aged over 80 years and whether there is any cancer-specific survival advantage for TRUS biopsy procedure. : Between January 2005 and December 2015, we studied outcomes of 200 patients (median age, 82 years) with elevated prostate-specific antigen (PSA) levels (>4.0 ng/mL) and/or abnormal digital rectal examination (DRE) who underwent TRUS biopsy. Each participant was followed up until death using an electronic system and a unique identifier in a defined geographical area. Cancer-specific and overall survival analyses were carried out utilising SPSS, while R Project was employed to construct and evaluate two nomograms survival duration and predict the risk of death post-biopsy. All statistical tests were two-tailed, with significance set at < 0.05. : Amongst the participants, only 24 patients were alive at the end of follow-up (median age, 91 years). The PSA levels ranged from 4.88 to 102.7 ng/mL. Log-rank and Breslow tests indicated that higher PSA levels, the development of metastases, and ISUP grade group 8-10 were associated with shorter survival times. Age, co-morbid conditions, and tumour type were incorporated into the nomogram due to their clinical significance. Patients aged <81 years had lower mortality risk, while those aged >88 years faced higher mortality risks. Complications from the biopsy increased mortality risks in both cancerous and benign cases, and metastasis significantly heightened the likelihood of death. However, co-morbid conditions did not influence survival probability. : Our findings underscore that older age (specifically 80 years and above), high Gleason score, metastasis, and elevated PSA levels are predictive of poorer survival outcomes in elderly men following TRUS biopsy.

References

Klemann N, Roder M, Helgstrand J, Brasso K, Toft B, Vainer B . Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study. Lancet Oncol. 2017; 18(2):221-229. DOI: 10.1016/S1470-2045(17)30025-6. View

Scosyrev E, Messing E, Mohile S, Golijanin D, Wu G . Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer. 2011; 118(12):3062-70. DOI: 10.1002/cncr.26392. View

Futterer J, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A . Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. Eur Urol. 2015; 68(6):1045-53. DOI: 10.1016/j.eururo.2015.01.013. View

Shigehara K, Miyagi T, Nakashima T, Shimamura M . Acute bacterial prostatitis after transrectal prostate needle biopsy: clinical analysis. J Infect Chemother. 2008; 14(1):40-3. DOI: 10.1007/s10156-007-0570-3. View

Carter H, Piantadosi S, Isaacs J . Clinical evidence for and implications of the multistep development of prostate cancer. J Urol. 1990; 143(4):742-6. DOI: 10.1016/s0022-5347(17)40078-4. View

Bernard B, Burnett C, Sweeney C, Rider J, Sridhar S . Impact of age at diagnosis of de novo metastatic prostate cancer on survival. Cancer. 2019; 126(5):986-993. DOI: 10.1002/cncr.32630. View

Chiang I, Chang S, Pu Y, Huang K, Yu H, Huang C . Major complications and associated risk factors of transrectal ultrasound guided prostate needle biopsy: a retrospective study of 1875 cases in taiwan. J Formos Med Assoc. 2007; 106(11):929-34. DOI: 10.1016/S0929-6646(08)60063-7. View

Sheikh M, Hussein A, Kehinde E, Al-Saeed O, Rad A, Ali Y . Patients' tolerance and early complications of transrectal sonographically guided prostate biopsy: prospective study of 300 patients. J Clin Ultrasound. 2005; 33(9):452-6. DOI: 10.1002/jcu.20168. View

Mohamed Z, Dominguez-Escrig J, Vasdev N, Bharathan B, Greene D . The prognostic value of transrectal ultrasound guided biopsy in patients over 70 years old with a prostate specific Antigen (PSA) level ≤ 15 ng/ml and normal digital rectal examination: a 10-year prospective follow-up study of 427 consecutive.... Urol Oncol. 2012; 31(8):1489-96. DOI: 10.1016/j.urolonc.2012.04.005. View

10.

Pinkhasov G, Lin Y, Palmerola R, Smith P, Mahon F, Kaag M . Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases. BJU Int. 2012; 110(3):369-74. DOI: 10.1111/j.1464-410X.2011.10926.x. View

11.

Anai S, West C, Chang M, Nakamura K, Pendleton J, Rosser C . Outcomes of men who present with elevated serum PSA (>20 ng/mL) to an inner-city hospital. J Natl Med Assoc. 2007; 99(8):895-9. PMC: 2574301. View

12.

Kapoor D, Klimberg I, Malek G, Wegenke J, Cox C, Patterson A . Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology. 1998; 52(4):552-8. DOI: 10.1016/s0090-4295(98)00296-9. View

13.

Barone B, Napolitano L, Calace F, Biondo D, Napodano G, Grillo M . Reliability of Multiparametric Magnetic Resonance Imaging in Patients with a Previous Negative Biopsy: Comparison with Biopsy-Naïve Patients in the Detection of Clinically Significant Prostate Cancer. Diagnostics (Basel). 2023; 13(11). PMC: 10253019. DOI: 10.3390/diagnostics13111939. View

14.

Dewey M, Schink T, Dewey C . Claustrophobia during magnetic resonance imaging: cohort study in over 55,000 patients. J Magn Reson Imaging. 2007; 26(5):1322-7. DOI: 10.1002/jmri.21147. View

15.

Nam R, Saskin R, Lee Y, Liu Y, Law C, Klotz L . Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2010; 183(3):963-8. DOI: 10.1016/j.juro.2009.11.043. View

16.

Osama S, Serboiu C, Taciuc I, Angelescu E, Petcu C, Priporeanu T . Current Approach to Complications and Difficulties during Transrectal Ultrasound-Guided Prostate Biopsies. J Clin Med. 2024; 13(2). PMC: 10816968. DOI: 10.3390/jcm13020487. View

17.

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

18.

Zhang Z, Cai Q, Wang J, Yao Z, Ji F, Hang Y . Development and validation of a nomogram to predict cancer-specific survival in nonsurgically treated elderly patients with prostate cancer. Sci Rep. 2023; 13(1):17719. PMC: 10584808. DOI: 10.1038/s41598-023-44911-z. View

19.

Enlund A, Varenhorst E . Morbidity of ultrasound-guided transrectal core biopsy of the prostate without prophylactic antibiotic therapy. A prospective study in 415 cases. Br J Urol. 1997; 79(5):777-80. DOI: 10.1046/j.1464-410x.1997.00144.x. View

20.

Rodriguez L, Terris M . Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol. 1998; 160(6 Pt 1):2115-20. DOI: 10.1097/00005392-199812010-00045. View